GSK PLC Sponsored ADR $GSK Shares Sold by Sound Income Strategies LLC

Sound Income Strategies LLC lowered its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 4.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 412,057 shares of the pharmaceutical company’s stock after selling 19,199 shares during the period. Sound Income Strategies LLC’s holdings in GSK were worth $17,900,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Twin Peaks Wealth Advisors LLC purchased a new position in shares of GSK during the 2nd quarter worth approximately $25,000. SOA Wealth Advisors LLC. grew its holdings in GSK by 252.1% during the 2nd quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 605 shares during the last quarter. CoreFirst Bank & Trust purchased a new position in GSK during the second quarter worth $33,000. MTM Investment Management LLC acquired a new position in shares of GSK in the second quarter worth $37,000. Finally, ST Germain D J Co. Inc. raised its holdings in shares of GSK by 225.2% in the second quarter. ST Germain D J Co. Inc. now owns 1,704 shares of the pharmaceutical company’s stock worth $65,000 after acquiring an additional 1,180 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Up 0.6%

Shares of NYSE GSK opened at $48.58 on Friday. The stock has a market capitalization of $99.07 billion, a PE ratio of 13.72, a P/E/G ratio of 1.32 and a beta of 0.45. The company has a quick ratio of 0.55, a current ratio of 0.84 and a debt-to-equity ratio of 0.95. The firm has a fifty day moving average of $46.81 and a 200-day moving average of $42.13. GSK PLC Sponsored ADR has a 52-week low of $31.72 and a 52-week high of $49.44.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.22. The firm had revenue of $11.35 billion for the quarter, compared to analysts’ expectations of $8.21 billion. GSK had a return on equity of 48.64% and a net margin of 17.16%.The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.50 earnings per share. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. On average, analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 8th. Investors of record on Friday, November 14th will be given a dividend of $0.4171 per share. This represents a $1.67 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date of this dividend is Friday, November 14th. GSK’s dividend payout ratio is 46.33%.

Insider Buying and Selling

In other GSK news, major shareholder Plc Gsk purchased 1,470,000 shares of GSK stock in a transaction on Thursday, December 11th. The shares were purchased at an average cost of $19.00 per share, with a total value of $27,930,000.00. Following the completion of the transaction, the insider directly owned 18,245,691 shares in the company, valued at approximately $346,668,129. This represents a 8.76% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.00% of the company’s stock.

Wall Street Analyst Weigh In

GSK has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of GSK in a research note on Monday, December 15th. HSBC reaffirmed a “reduce” rating on shares of GSK in a research note on Wednesday, December 10th. Jefferies Financial Group reissued a “buy” rating on shares of GSK in a research report on Monday, October 27th. Wall Street Zen raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 5th. Finally, Bank of America upgraded GSK from an “underperform” rating to a “neutral” rating in a report on Tuesday, November 25th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, GSK has an average rating of “Hold” and a consensus target price of $44.13.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.